skip to main content
1800 500 258

BCNA News 25 Nov 2015

For Benefit Medicines to support BCNA

BCNA is delighted to announce a new funding agreement with For Benefit Medicines (FBM).

For Benefit Medicines is Australia’s first not-for-profit pharmaceutical company. It has been established under a social enterprise model, with the sole purpose of distributing 100% of its profits to patient support and medical research in Australia, rather than to shareholders.

FBM has two breast cancer drugs now available for use in Australia – generic versions of the hormone therapies anastrozole and letrozole. In line with their slogan, Now every cloud has a silver lining, FBM is providing a silver lining for those affected by breast cancer by ensuring all profits from the sale of these drugs are invested back into breast cancer.

Under their model, 50% of the profits will be directed to support people living with breast cancer and 50% into research for breast cancer treatments and a cure.

BCNA has agreed to be the recipient of the patient support share of their profits. FBM will donate the research share to the Breast Cancer Institute of Australia, which is the fundraising body supporting the Australia and New Zealand Breast Cancer Trials Group.

BCNA CEO Christine Nolan said she is excited by FBM’s decision to support BCNA.

We are very grateful that the Directors of FBM are determined to keep their profits in Australia to benefit people affected by breast cancer. The funds coming to BCNA will help people living with breast cancer now, while the research funding will help those diagnosed in the future.

All FBM medications are approved by the Australian Government’s Therapeutic Goods Administration (TGA) for use in Australia, and are required to meet the same strict regulations applied to the original brand with regard to quality, safety and effectiveness.

FBM’s generic medications are available in pharmacies as Anastrozole FBM and Letrozole FBM.

Importantly, FBM medicines are listed on the Pharmaceutical Benefits Scheme (PBS) and will cost the same as current breast cancer medications.